PANTHERx Rare Collaborates with Soleno Therapeutics for VYKAT XR
PANTHERx Rare has been chosen by Soleno Therapeutics as the specialty pharmacy to handle the distribution of VYKAT XR (diazoxide choline extended-release tablets). This groundbreaking oral treatment is designed for individuals aged four and older who are dealing with hyperphagia associated with Prader-Willi syndrome (PWS). Notably, VYKAT XR holds the distinction of being the first and only FDA-approved therapy for hyperphagia in PWS.
Understanding Hyperphagia and PWS
Prader-Willi syndrome is a challenging genetic disorder occurring in about one in every 15,000 births. One of its most daunting symptoms is hyperphagia, which leads to unrelenting hunger. Those with PWS often face intense cravings for food, posing risks that can endanger their lives. Without proper management, hyperphagia can result in life-threatening situations, including stomach ruptures or choking incidents.
The Impact of VYKAT XR on Patients
Bansi Nagji, the CEO of PANTHERx Rare Pharmacy, expressed the company’s enthusiasm over their new role in distributing VYKAT XR. He believes that this therapy can greatly enhance the quality of life for patients suffering from PWS. The supportive initiatives by PANTHERx Rare will enable these individuals, along with their families, to gain access to a much-needed medical solution, fostering hope amidst the challenges of dealing with a rare condition.
PANTHERx Rare: A Leader in Specialty Pharmacy
PANTHERx Rare is not just another pharmacy; it’s a specialized entity devoted to rare and orphan diseases. Renowned as The Rare Disease Pharmacy®, PANTHERx is instrumental in transforming lives through innovative therapies, clinical excellence, and comprehensive access solutions. This commitment to improving patient outcomes in rare diseases is exemplified by their dual accreditations—one from the Accreditation Commission for Health Care (ACHC) and the other from the Utilization Review Accreditation Commission (URAC), recognizing them as a Rare Disease Center of Excellence.
Commitment to Excellence
PANTHERx Rare has earned a reputation for excellence, having been awarded the MMIT Patient Choice Award multiple times. Their focus on patient satisfaction and engagement speaks volumes about their dedication to improving access to essential treatments.
Headquarters and Licensure
Headquartered in Pennsylvania, PANTHERx is proud to serve across all fifty states and U.S. territories, ensuring that patients can access vital medications regardless of where they live. This expansive reach is crucial for families affected by rare diseases, providing them with the support they desperately need.
Frequently Asked Questions
What is VYKAT XR?
VYKAT XR is an FDA-approved treatment designed specifically for alleviating hyperphagia in individuals with Prader-Willi syndrome.
Who is PANTHERx Rare?
PANTHERx Rare is a specialty pharmacy focused on providing support and access to treatments for patients with rare and orphan diseases.
What does hyperphagia entail?
Hyperphagia refers to an uncontrollable craving for food, which can be life-threatening for individuals with PWS.
How can PANTHERx assist with VYKAT XR?
PANTHERx Rare is responsible for the distribution of VYKAT XR and will support patients and their families in obtaining the medication.
Why is PANTHERx recognized?
PANTHERx has received multiple awards for patient satisfaction, highlighting its commitment to providing excellent care and access to rare disease treatments.
